Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Taro Pharm Inds (TARO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 4,736,503
  • Shares Outstanding, K 41,030
  • Annual Sales, $ 950,750 K
  • Annual Income, $ 540,930 K
  • 36-Month Beta 0.77
  • Price/Sales 5.00
  • Price/Cash Flow N/A
  • Price/Book 2.37

Price Performance

See More
Period Period Low Period High Performance
1-Month
113.58 +0.55%
on 04/24/17
124.52 -8.28%
on 03/29/17
-2.76 (-2.36%)
since 03/24/17
3-Month
100.24 +13.94%
on 01/31/17
124.52 -8.28%
on 03/29/17
+12.08 (+11.83%)
since 01/25/17
52-Week
92.28 +23.76%
on 11/03/16
150.75 -24.24%
on 06/09/16
-29.86 (-20.73%)
since 04/25/16

Most Recent Stories

More News
Taro Provides Results for December 31, 2016

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three and nine months ended December 31, 2016.

TARO : 114.21 (-1.07%)
Taro to Announce Third Quarter Results on February 9, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2016, after the close of...

TARO : 114.21 (-1.07%)
Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA

Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque...

ENZ : 8.72 (-0.91%)
TARO : 114.21 (-1.07%)
PRGO : 67.81 (+1.13%)
BIIB : 286.89 (+3.62%)
TARO 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Taro Pharmaceutical Industries Ltd. - TARO

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until December...

TARO : 114.21 (-1.07%)
Taro Announces Sale of U.S. Rights to Keveyis(R) to Strongbridge Biopharma plc

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced the sale of U.S. rights to Keveyis(R) (dichlorphenamide) to Strongbridge Biopharma plc (Strongbridge),...

SBBP : 4.80 (+9.09%)
TARO : 114.21 (-1.07%)
Strongbridge Biopharma plc Announces $35 Million Equity Financing

Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs,...

SBBP : 4.80 (+9.09%)
TARO : 114.21 (-1.07%)
DEADLINE ALERT: Brower Piven Notifies Shareholders of Upcoming Deadline In Class Action Lawsuit And Urges Those With Losses In Excess of $100,000 From Investment In Taro Pharmaceutical Industries Ltd To Contact The Firm - TARO

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of...

TARO : 114.21 (-1.07%)
TARO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Taro Pharmaceutical Industries Ltd. and a Lead Plaintiff Deadline of December 27, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Taro Pharmaceutical Industries...

TARO : 114.21 (-1.07%)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Taro Pharmaceutical Industries Ltd. To Contact The Firm Before Imminent Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Taro Pharmaceutical Industries Ltd. ("Taro" or the "Company") (NYSE:TARO) of the December 27, 2016 deadline to seek the...

TARO : 114.21 (-1.07%)
SHAREHOLDER REMINDER: Deadline in Class Action Lawsuit Filed Against Taro Pharmaceutical Industries Ltd. - TARO

RADNOR, PA / ACCESSWIRE / December 19, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") shareholders that a class...

TARO : 114.21 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals...

See More

Support & Resistance

2nd Resistance Point 117.28
1st Resistance Point 115.74
Last Price 114.21
1st Support Level 113.25
2nd Support Level 112.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.